Lovastatin ( DrugBank: Lovastatin )
11 diseases
ID | Disease name (Link within this page) | Number of trials |
---|---|---|
6 | Parkinson disease | 1 |
34 | Neurofibromatosis | 5 |
46 | Malignant rheumatoid arthritis | 1 |
79 | Homozygous familial hypercholesterolemia | 1 |
156 | Rett syndrome | 1 |
160 | Congenital ichthyosis | 1 |
195 | Noonan syndrome | 1 |
206 | Fragile X syndrome | 3 |
263 | Cerebrotendinous xanthomatosis | 1 |
280 | Huge arteriovenous malformation with cervicofacial or limb lesion | 1 |
310 | Congenital anomalies syndrome | 1 |
6. Parkinson disease
Clinical trials : 2,298 / Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03242499 (ClinicalTrials.gov) | May 15, 2017 | 1/8/2017 | Lovastatin as a Neuroprotective Treatment for Early Stage Parkinson's Disease | Lovastatin as a Neuroprotective Treatment for Early Stage Parkinson's Disease: a Single-center, Double-blind, Placebo-controlled Randomized Trial | Parkinson Disease | Drug: Lovastatin;Drug: Placebo | National Taiwan University Hospital | NULL | Recruiting | 30 Years | 90 Years | All | 80 | Phase 2 | Taiwan |
34. Neurofibromatosis
Clinical trials : 137 / Drugs : 213 - (DrugBank : 76) / Drug target genes : 87 - Drug target pathways : 200
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03826940 (ClinicalTrials.gov) | February 19, 2019 | 23/1/2019 | From Molecules to Cognition: Inhibitory Mechanisms in ASD and NF1 | Linking Inhibition From Molecular to Systems and Cognitive Levels: a Preclinical and Clinical Approach in Autism Spectrum Disorders and Neurofibromatosis. | Autism Spectrum Disorder;Neurofibromatosis 1 | Drug: Lovastatin 60 MG;Drug: Placebos | University of Coimbra | NULL | Completed | 16 Years | 65 Years | All | 16 | N/A | Portugal |
2 | EUCTR2016-005022-10-DE (EUCTR) | 13/02/2018 | 09/11/2017 | Improvement of synaptic plasticity and cognitive function in RAS pathway disorders | Improvement of synaptic plasticity and cognitive function in RAS pathway disorders | Noonan Syndrom and Neurofibromatosis Type 1 MedDRA version: 20.0;Level: PT;Classification code 10029748;Term: Noonan syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 20.0;Classification code 10029268;Term: Neurofibromatosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Not possible to specify | Product Name: Lovastatin INN or Proposed INN: Lovastatin Other descriptive name: LOVASTATIN Product Name: Lamotrigin beta INN or Proposed INN: Lamotrigin | Technische Universität München, Fakultät für Medizin | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 30 | Phase 2 | Germany | ||
3 | NCT02964884 (ClinicalTrials.gov) | November 2016 | 9/11/2016 | Interventions for Reading Disabilities in NF1 | Neurobiology and Treatment of Reading Disability in NF1 | Neurofibromatosis Type 1;Learning Disability;Reading Disability;NF1 | Drug: Lovastatin;Behavioral: reading tutoring intervention;Drug: Placebo Oral Tablet;Behavioral: Other Academic sham tutoring | Vanderbilt University | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Recruiting | 8 Years | 20 Years | All | 120 | Phase 2 | United States |
4 | NCT00352599 (ClinicalTrials.gov) | September 2009 | 13/7/2006 | Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1) | Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1) | Neurofibromatosis 1 | Drug: Lovastatin;Drug: placebo pill | University of California, Los Angeles | NULL | Completed | 10 Years | 50 Years | Both | 44 | Phase 1 | United States |
5 | NCT00853580 (ClinicalTrials.gov) | July 2009 | 23/2/2009 | A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1 | A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1 | Neurofibromatosis Type 1 | Drug: Lovastatin ™;Device: placebo | University of Alabama at Birmingham | Boston Children's Hospital;Children's Hospital of Philadelphia;Children's National Research Institute;Children's Hospital Medical Center, Cincinnati;National Cancer Institute (NCI);University of Chicago;University of Utah;Washington University School of Medicine;Sydney Children's Hospitals Network;University of Texas Southwestern Medical Center | Completed | 8 Years | 15 Years | All | 146 | Phase 2 | United States;Australia |
46. Malignant rheumatoid arthritis
Clinical trials : 4,325 / Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00302952 (ClinicalTrials.gov) | November 6, 2007 | 13/3/2006 | Lovastatin for the Treatment of Mildly Active Rheumatoid Arthritis | A Double Blind, Placebo Controlled, Phase II, Randomized Study of Lovastatin Therapy in the Treatment of Mildly Active Rheumatoid Arthritis | Rheumatoid Arthritis | Drug: Lovastatin;Drug: Placebo | National Institute of Allergy and Infectious Diseases (NIAID) | Autoimmunity Centers of Excellence | Terminated | 18 Years | 70 Years | All | 64 | Phase 2 | United States |
79. Homozygous familial hypercholesterolemia
Clinical trials : 142 / Drugs : 114 - (DrugBank : 29) / Drug target genes : 9 - Drug target pathways : 18
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03510715 (ClinicalTrials.gov) | August 31, 2018 | 18/4/2018 | An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia | An Open-Label Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia | Hypercholesterolemia | Drug: Alirocumab SAR236553 (REGN727);Drug: Rosuvastatin;Drug: Ezetimibe;Drug: Cholestyramine;Drug: Nicotinic acid;Drug: Fenofibrate;Drug: Omega-3 fatty acids;Drug: Atorvastatin;Drug: Simvastatin;Drug: Fluvastatin;Drug: Pravastatin;Drug: Lovastatin | Sanofi | Regeneron Pharmaceuticals | Completed | 8 Years | 17 Years | All | 18 | Phase 3 | Brazil;Canada;Denmark;Mexico;Netherlands;Russian Federation;Slovenia;Spain;Taiwan;Turkey;Austria;France;Italy;Norway;United States |
156. Rett syndrome
Clinical trials : 40 / Drugs : 53 - (DrugBank : 19) / Drug target genes : 77 - Drug target pathways : 113
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02563860 (ClinicalTrials.gov) | July 2015 | 20/7/2015 | Pharmacological Treatment of Rett Syndrome With Statins | Pharmacological Treatment of Rett Syndrome With 3-Hydroxy-3 Methylglutaryl-coenzyme A Reductase Inhibitor-Lovastatin (Mevacor) | Rett Syndrome | Drug: Lovastatin | Montefiore Medical Center | Rett Syndrome Research Trust | Completed | 3 Years | N/A | Female | 20 | Phase 2 | United States |
160. Congenital ichthyosis
Clinical trials : 36 / Drugs : 72 - (DrugBank : 21) / Drug target genes : 18 - Drug target pathways : 111
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01110642 (ClinicalTrials.gov) | July 2011 | 22/4/2010 | Novel Treatment for Syndromic Ichthyoses | Open-label, Pilot Study to Assess Cholesterol-Lovastatin Solution in the Treatment of Syndromic Ichthyoses | Syndromic Ichthyoses;CHILD Syndrome;Smith Lemli Opitz Syndrome;Conradi Syndrome | Drug: Lovastatin | Northwestern University | NULL | Withdrawn | 1 Year | N/A | Both | 0 | Phase 2 | United States |
195. Noonan syndrome
Clinical trials : 14 / Drugs : 15 - (DrugBank : 5) / Drug target genes : 2 - Drug target pathways : 9
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2016-005022-10-DE (EUCTR) | 13/02/2018 | 09/11/2017 | Improvement of synaptic plasticity and cognitive function in RAS pathway disorders | Improvement of synaptic plasticity and cognitive function in RAS pathway disorders | Noonan Syndrom and Neurofibromatosis Type 1 MedDRA version: 20.0;Level: PT;Classification code 10029748;Term: Noonan syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 20.0;Classification code 10029268;Term: Neurofibromatosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Not possible to specify | Product Name: Lovastatin INN or Proposed INN: Lovastatin Other descriptive name: LOVASTATIN Product Name: Lamotrigin beta INN or Proposed INN: Lamotrigin | Technische Universität München, Fakultät für Medizin | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 30 | Phase 2 | Germany |
206. Fragile X syndrome
Clinical trials : 104 / Drugs : 87 - (DrugBank : 32) / Drug target genes : 54 - Drug target pathways : 79
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02680379 (ClinicalTrials.gov) | March 2016 | 25/1/2016 | Combined Treatment of Minocycline and Lovastatin to Treat Individuals With Fragile X Syndrome | A Pilot Study Exploring the Safety and Synergistic Effect of a Minocycline/Lovastatin Combined Treatment on the Behavior of Individuals With Fragile X Syndrome; Validation of New Biochemical and Neurophysiological Markers (LovaMiX) | Fragile X Syndrome | Drug: Minocycline, then Minocycline/Lovastatin;Drug: Lovastatin, then Minocycline/Lovastatin | Université de Sherbrooke | FRAXA Research Foundation | Completed | 8 Years | 45 Years | All | 22 | Phase 2 | Canada |
2 | NCT02642653 (ClinicalTrials.gov) | January 2016 | 21/12/2015 | Combining Lovastatin and a Parent-Implemented Language Intervention for Fragile X Syndrome | Combining Lovastatin and a Parent-Implemented Language Intervention in a Multimodal Treatment for Fragile X Syndrome | Fragile X Syndrome;Genetic Diseases | Drug: Lovastatin;Other: Placebo | University of California, Davis | NULL | Completed | 10 Years | 17 Years | All | 30 | Phase 4 | United States |
3 | NCT02998151 (ClinicalTrials.gov) | January 2016 | 1/12/2016 | Neurophysiological and Acute Pharmacological Studies in FXS Patients | Neurophysiological and Acute Pharmacological Studies in FXS Patients | Fragile X Syndrome | Drug: Acamprosate;Drug: Lovastatin;Drug: Minocycline;Drug: Placebo;Drug: Baclofen | Children's Hospital Medical Center, Cincinnati | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Completed | 15 Years | 55 Years | All | 29 | Early Phase 1 | United States |
263. Cerebrotendinous xanthomatosis
Clinical trials : 5 / Drugs : 10 - (DrugBank : 2) / Drug target genes : 2 - Drug target pathways : 4
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00004346 (ClinicalTrials.gov) | January 1996 | 18/10/1999 | Phase II Study of Cholesterol- and Cholestanol-Free Diet, Lovastatin, and Chenodeoxycholic Acid for Cerebrotendinous Xanthomatosis | Effects of Diet and Medication in Patients With Cerebrotendinous Xanthomatosis (CTX) | Cerebrotendinous Xanthomatosis | Drug: chenodeoxycholic acid;Drug: lovastatin | National Center for Research Resources (NCRR) | Oregon Health and Science University | Recruiting | N/A | N/A | Both | 5 | Phase 2 | United States |
280. Huge arteriovenous malformation with cervicofacial or limb lesion
Clinical trials : 25 / Drugs : 29 - (DrugBank : 15) / Drug target genes : 14 - Drug target pathways : 153
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04297033 (ClinicalTrials.gov) | January 1, 2021 | 21/2/2020 | Lovastatin for Treatment of Brain Arteriovenous Malformations | Lovastatin for Treatment of Brain Arteriovenous Malformations:a Double-blind, Placebo-controlled Randomized Trial | Cerebral Arteriovenous Malformation | Drug: Lovastatin;Drug: Placebo | Beijing Tiantan Hospital | NULL | Not yet recruiting | 18 Years | N/A | All | 1244 | Phase 2 | China |
310. Congenital anomalies syndrome
Clinical trials : 10 / Drugs : 18 - (DrugBank : 10) / Drug target genes : 3 - Drug target pathways : 7
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01110642 (ClinicalTrials.gov) | July 2011 | 22/4/2010 | Novel Treatment for Syndromic Ichthyoses | Open-label, Pilot Study to Assess Cholesterol-Lovastatin Solution in the Treatment of Syndromic Ichthyoses | Syndromic Ichthyoses;CHILD Syndrome;Smith Lemli Opitz Syndrome;Conradi Syndrome | Drug: Lovastatin | Northwestern University | NULL | Withdrawn | 1 Year | N/A | Both | 0 | Phase 2 | United States |